ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines

被引:32
|
作者
Tang, Ying [1 ]
Hou, Jingming [2 ]
Li, Guanghui [1 ]
Song, Zongchang [1 ]
Li, Xiaojing [1 ]
Yang, Cui [1 ]
Liu, Wenying [1 ]
Hu, Yide [1 ]
Xu, Yu [3 ]
机构
[1] Third Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing 400038, Peoples R China
[2] Chinese PLA Beijing Army Gen Hosp, Dept Orthoped, Beijing 100700, Peoples R China
[3] Third Mil Med Univ, Inst Resp Dis, Xinqiao Hosp, Chongqing 400038, Peoples R China
基金
中国国家自然科学基金;
关键词
ABCG2; drug resistance; NSCLC; symmetric division; asymmetric division; MULTIDRUG-RESISTANCE; STEM-CELLS; ASYMMETRIC DIVISION; DRUG-RESISTANCE; IN-VIVO; EXPRESSION; CHEMOTHERAPY; TRANSPORTER; SUPPRESSION; PHENOTYPE;
D O I
10.3892/or.2014.3470
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of ABCG2 is considered a major mechanism of cancer drug resistance. Recent studies have shown that ABCG2 can regulate the switch between symmetric and asymmetric cell division in adult stem cells; however, the relationship between ABCG2 and cell division in drug-resistant cancer cells remains to be determined. In the present study, we demonstrated that ABCG2 is involved in the cell division of drug-resistant cancer cells. We first established drug-resistant H460 and A549 cell lines by repeated exposure to cisplatin and found that the expression of ABCG2 in these cell lines was significantly increased. As evidenced by PKH-26 staining, these drug-resistant cell lines favored symmetric division, which differed from the asymmetric division of the parental cells. Furthermore, we established stable ABCG2-overexpressing and stable shRNA-ABCG2-knock-down cell lines to evaluate the potential role of ABCG2 in cancer cell division. The results showed that overexpression of ABCG2 in A549 parental cells significantly increased the proportion of symmetric division, whereas knockdown of ABCG2 in drug-resistant A549 cells significantly increased the proportion of asymmetric division. Taken together, our findings suggest that ABCG2 is involved in the modulation of cancer drug resistance by regulating the pattern of cell division. The present study provides novel insight into the role of ABCG2 in cancer treatment resistance.
引用
收藏
页码:2168 / 2174
页数:7
相关论文
共 50 条
  • [1] ABCG2 Gene Expression in Non-Small Cell Lung Cancer
    Jelen, Agnieszka
    Zebrowska-Nawrocka, Marta
    Lochowski, Mariusz
    Szmajda-Krygier, Dagmara
    Balcerczak, Ewa
    BIOMEDICINES, 2024, 12 (10)
  • [2] A meta-analysis of ABCG2 gene polymorphism and non-small cell lung cancer outcomes
    Fu, Lei
    Wang, Rong
    Yin, Ling
    Shang, Xiaopu
    Zhang, Runtong
    Zhang, Pengjun
    GENETICS AND MOLECULAR BIOLOGY, 2019, 42 (04)
  • [3] Epigenetic activation of FOXF1 confers cancer stem cell properties to cisplatin-resistant non-small cell lung cancer
    Zhao, Jian
    Xue, Xingyang
    Fu, Wenfan
    Dai, Lu
    Jiang, Zeyong
    Zhong, Shengpeng
    Deng, Boyun
    Yin, Jun
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 56 (05) : 1083 - 1092
  • [4] GENERATION AND CHARACTERISATION OF CISPLATIN-RESISTANT NON-SMALL CELL LUNG CANCER CELL LINES DISPLAYING STEM-LIKE FEATURES
    Barr, Martin P.
    Fennell, Dean A.
    O'Byrne, Kenneth J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S676 - S677
  • [5] Comprehensive analysis of circular RNA expression profiles in cisplatin-resistant non-small cell lung cancer cell lines
    Song, Lin
    Cui, Zhilei
    Guo, Xuejun
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2020, 52 (09) : 944 - 953
  • [6] Cisplatin-resistant A549 non-small cell lung cancer cells can be identified by increased mitochondrial mass and are sensitive to pemetrexed treatment
    Gao, Yanyun
    Dorn, Patrick
    Liu, Shengchen
    Deng, Haibin
    Hall, Sean R. R.
    Peng, Ren-Wang
    Schmid, Ralph A.
    Marti, Thomas M.
    CANCER CELL INTERNATIONAL, 2019, 19 (01)
  • [7] Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer
    Shoji, Tetsuaki
    Kikuchi, Eiki
    Kikuchi, Junko
    Takashima, Yuta
    Furuta, Megumi
    Takahashi, Hirofumi
    Tsuji, Kosuke
    Maeda, Makie
    Kinoshita, Ichiro
    Dosaka-Akita, Hirotoshi
    Sakakibara-Konishi, Jun
    Konno, Satoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 843 - 853
  • [8] Nedaplatin sensitization of cisplatin-resistant human non-small cell lung cancer cells
    Wang, Huan
    Zhu, Xiaoli
    Huang, Jing
    Chen, Pingsheng
    Han, Shuhua
    Yan, Xing
    ONCOLOGY LETTERS, 2016, 11 (04) : 2566 - 2572
  • [9] Downregulated ABCG2 Enhances Sensitivity to Topoisomerase I Inhibitor in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Non-small Cell Lung Cancer
    Ohtsuka, Kouki
    Ohnishi, Hiroaki
    Morii, Takeshi
    Fujiwara, Masachika
    Kishino, Tomonori
    Ogura, Wataru
    Chiba, Misaki
    Matsushima, Satsuki
    Goya, Tomoyuki
    Watanabe, Takashi
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (11) : 1726 - 1733
  • [10] Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor
    Zuco, Valentina
    Cassinelli, Giuliana
    Cossa, Giacomo
    Gatti, Laura
    Favini, Enrica
    Tortoreto, Monica
    Cominetti, Denis
    Scanziani, Eugenio
    Castiglioni, Vittoria
    Cincinelli, Raffaella
    Giannini, Giuseppe
    Zunino, Franco
    Zaffaroni, Nadia
    Lanzi, Cinzia
    Perego, Paola
    BIOCHEMICAL PHARMACOLOGY, 2015, 94 (02) : 79 - 90